Page last updated: 2024-08-17

carbostyril and Lupus Erythematosus, Systemic

carbostyril has been researched along with Lupus Erythematosus, Systemic in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sanz, I1
Parikh, SV; Rovin, BH1
Hahn, BH; Lourenço, EV; Palma-Diaz, MF; Skaggs, BJ; Wong, M1
Furie, R; Narain, S1
Alsina, M; Bennàssar, A; Guilabert, A; Mascaró, JM; Pintor, L1
Bang, L; Harris, TB; Mian, A; Muscal, E1
Attademo, L; Moretti, P; Quartesan, R1
Bokarewa, M; Carlsten, H; Jonsson, C; Svensson, L; Tarkowski, A1

Reviews

2 review(s) available for carbostyril and Lupus Erythematosus, Systemic

ArticleYear
Lupus nephritis: the evolving role of novel therapeutics.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2014, Volume: 63, Issue:4

    Topics: Abatacept; Acute Kidney Injury; Adolescent; Algorithms; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Apoptosis; Autoantibodies; B-Lymphocytes; Cytokine TWEAK; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Humans; Immunoconjugates; Immunosuppressive Agents; Interleukin-6; Lupus Erythematosus, Systemic; Lupus Nephritis; Quinolones; Remission Induction; Rituximab; Tumor Necrosis Factor Inhibitors

2014
Update on clinical trials in systemic lupus erythematosus.
    Current opinion in rheumatology, 2016, Volume: 28, Issue:5

    Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Clinical Trials as Topic; Cyclosporine; Herpes Zoster; Humans; Immunosuppressive Agents; Interferon Type I; Lupus Erythematosus, Systemic; Lupus Nephritis; Maintenance Chemotherapy; Peptide Fragments; Plasma Cells; Quinolones; Recombinant Fusion Proteins; Remission Induction; T-Lymphocytes; Tacrolimus; Treatment Outcome

2016

Other Studies

6 other study(ies) available for carbostyril and Lupus Erythematosus, Systemic

ArticleYear
New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research.
    Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Biomedical Research; Calcineurin Inhibitors; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Cytokines; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Inflammasomes; Lupus Erythematosus, Systemic; Lymphocyte Depletion; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; Quinolones; Rheumatology

2017
Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.
    Arthritis & rheumatology (Hoboken, N.J.), 2014, Volume: 66, Issue:3

    Topics: Animals; Disease Models, Animal; Interferon-gamma; Interleukin-10; Interleukin-17; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphocytes; Mice; Myeloid Cells; Quinolones; Tumor Necrosis Factor-alpha

2014
Treatment of delusional parasitosis with aripiprazole.
    Archives of dermatology, 2009, Volume: 145, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; HIV Infections; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Piperazines; Quinolones; Skin Diseases, Parasitic

2009
Use of aripiprazole in adolescents with a history of lupus-associated psychosis and refractory psychiatric manifestations.
    Journal of psychiatric practice, 2011, Volume: 17, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Vasculitis, Central Nervous System; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Remission Induction; Treatment Outcome; Weight Gain

2011
[Efficacy of aripiprazole on cognitive and behavioral changes in a young woman with systemic lupus erythematosus].
    La Clinica terapeutica, 2012, Volume: 163, Issue:5

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Lupus Erythematosus, Systemic; Mental Disorders; Piperazines; Quinolones

2012
The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus.
    International immunopharmacology, 2004, Volume: 4, Issue:12

    Topics: Animals; Disease Models, Animal; Female; Immunity, Innate; Immunoglobulins; Immunologic Factors; Lupus Erythematosus, Systemic; Lymphocyte Activation; Male; Mice; Mice, Inbred MRL lpr; Quinolones; T-Lymphocytes; Transcription Factors

2004